Jack Kaye - Net Worth and Insider Trading

Jack Kaye Net Worth

The estimated net worth of Jack Kaye is at least $537,839 dollars as of 2025-04-16. Jack Kaye is the Director of Keryx Biopharmaceuticals Inc and owns about 141,400 shares of Keryx Biopharmaceuticals Inc (KERX) stock worth over $475,104. Jack Kaye is also the Director of uniQure NV and owns about 6,501 shares of uniQure NV (QURE) stock worth over $62,735. Details can be seen in Jack Kaye's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jack Kaye has not made any transactions after 2024-06-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of Jack Kaye

To

Jack Kaye Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jack Kaye owns 3 companies in total, including uniQure NV (QURE) , Dyadic International Inc (DYAI) , and Keryx Biopharmaceuticals Inc (KERX) .

Click here to see the complete history of Jack Kaye’s form 4 insider trades.

Insider Ownership Summary of Jack Kaye

Ticker Comapny Transaction Date Type of Owner
QURE uniQure NV 2024-06-13 director
DYAI Dyadic International Inc 2019-06-25 director
KERX Keryx Biopharmaceuticals Inc 2015-06-17 director

Jack Kaye Latest Holdings Summary

Jack Kaye currently owns a total of 2 stocks. Among these stocks, Jack Kaye owns 141,400 shares of Keryx Biopharmaceuticals Inc (KERX) as of December 6, 2010, with a value of $475,104 and a weighting of 88.34%. Jack Kaye also owns 6,501 shares of uniQure NV (QURE) as of June 13, 2024, with a value of $62,735 and a weighting of 11.66%.

Latest Holdings of Jack Kaye

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KERX Keryx Biopharmaceuticals Inc 2010-12-06 141,400 3.36 475,104
QURE uniQure NV 2024-06-13 6,501 9.65 62,735

Holding Weightings of Jack Kaye


Jack Kaye Form 4 Trading Tracker

According to the SEC Form 4 filings, Jack Kaye has made a total of 0 transactions in Keryx Biopharmaceuticals Inc (KERX) over the past 5 years. The most-recent trade in Keryx Biopharmaceuticals Inc is the sale of 20,000 shares on December 6, 2010, which brought Jack Kaye around $100,000.

According to the SEC Form 4 filings, Jack Kaye has made a total of 4 transactions in uniQure NV (QURE) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in uniQure NV is the sale of 2,218 shares on June 13, 2024, which brought Jack Kaye around $11,445.

Insider Trading History of Jack Kaye

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jack Kaye Trading Performance

GuruFocus tracks the stock performance after each of Jack Kaye's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jack Kaye is 107.95%. GuruFocus also compares Jack Kaye's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jack Kaye within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jack Kaye's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jack Kaye

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 55.13 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 54.16 LIMIT LIMIT LIMIT LIMIT LIMIT

Jack Kaye Ownership Network

Ownership Network List of Jack Kaye

No Data

Ownership Network Relation of Jack Kaye

Insider Network Chart

Jack Kaye Owned Company Details

What does uniQure NV do?

Who are the key executives at uniQure NV?

Jack Kaye is the director of uniQure NV. Other key executives at uniQure NV include director & CEO & Managing Director Matthew C Kapusta , Chief Financial Officer Christian Klemt , and Chief Medical Officer Walid Abi-saab .

uniQure NV (QURE) Insider Trades Summary

Over the past 18 months, Jack Kaye made no insider transaction in uniQure NV (QURE). Other recent insider transactions involving uniQure NV (QURE) include a net sale of 193,107 shares made by Matthew C Kapusta , a net sale of 47,008 shares made by Christian Klemt , and a net sale of 12,391 shares made by Pierre Caloz .

In summary, during the past 3 months, insiders sold 97,906 shares of uniQure NV (QURE) in total and bought 0 shares, with a net sale of 97,906 shares. During the past 18 months, 286,236 shares of uniQure NV (QURE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 286,236 shares.

uniQure NV (QURE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

uniQure NV Insider Transactions

No Available Data

Jack Kaye Mailing Address

Above is the net worth, insider trading, and ownership report for Jack Kaye. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Jack Kaye's mailing address is: New York X1 10022.